S. N. Michael Wong

Mr. S. N. Michael Wong

Department of Clinical Oncology, The University of Hong Kong, Hong Kong, China
orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 July 2023 in Cancers
Verified
Journal Article
Open access
PDF file
WCWing Lok Chan
Wing Lok Chan
XLXiaodong Liu
Xiaodong Liu
CWCarlos K H Wong
Carlos K H Wong
SWS. N. Michael Wong
S. N. Michael Wong
IWIan Yu-Hong Wong
Ian Yu-Hong Wong
DKDora LW Kwong
Dora LW Kwong
(1) Background: The effectiveness of adjuvant chemotherapy in older patients with gastric cancer after D2-gastrectomy is unclear. This study investigated the efficacy of adjuvant chemotherapy in elderly patients with stage II/III gastric cancer. (2) Methods: A real-world population-based retrospective cohort of patients aged ≥65 with stage II/III gastric cancer (n = 2616; median age: 73.5; 12.2% aged >80 years) treated between 1 January 1997 and 31 December 2020 were included. All data was retrieved from the Hong Kong Hospital Authority Clinical Management System (CMS). Clinical characteristics of those patients with and without adjuvant chemotherapy treatment were balanced after propensity score matching (PSM). In total, 732 patients treated with adjuvant chemotherapy were matched with 732 patients treated with surgery alone. Hazard ratios (HRs) estimated via Cox proportional hazards regression models were used to compare the overall survival (OS) and cancer-specific survival (CSS) of the two patient groups. (3) Results: Adjuvant chemotherapy was associated with better OS (37 vs. 25 months; HR: 0.80; 95% CI: 0.75–0.84; p < 0.001) than surgery alone. The OS benefit was observed in both the 65–80 (44 vs. 27 months; HR: 0.79; 95% CI: 0.74–0.84; p < 0.001) and >80 (14 vs. 11 months; HR: 0.82; 95% CI: 0.71–0.96; p < 0.001) age groups. A better CSS was observed in patients who received adjuvant chemotherapy than those who only had surgery (5-year CSS: 64.1% vs. 61.1%, HR: 0.85; 95% CI: 0.79–0.93; p < 0.001). (4) Conclusions: adjuvant chemotherapy significantly improved OS and CSS in older patients with stage II/III gastric cancer.

1 June 2023 in JCO Precision Oncology
Verified
Journal Article
Open access
TLTai-Chung Lam
Tai-Chung Lam
WCWilliam Chi-Shing Cho
William Chi-Shing Cho
JAJoseph Siu-Kie Au
Joseph Siu-Kie Au
Edmond SK MaEdmond SK Ma
Edmond SK Ma
SLStephen Tak-Sum Lam
Stephen Tak-Sum Lam
O(on behalf of the Precision Oncology Working Group (POWG)
on behalf of the Precision Oncology Working Group (POWG)
BACKGROUND: Next-generation sequencing comprehensive genomic panels (NGS CGPs) have enabled the delivery of tailor-made therapeutic approaches to improve survival outcomes in patients with cancer. Within the China Greater Bay Area (GBA), territorial differences in clinical practices and health care systems and strengthening collaboration warrant a regional consensus to consolidate the development and integration of precision oncology (PO). Therefore, the Precision Oncology Working Group (POWG) formulated standardized principles for the clinical application of molecular profiling, interpretation of genomic alterations, and alignment of actionable mutations with sequence-directed therapy to deliver clinical services of excellence and evidence-based care to patients with cancer in the China GBA. METHODS: Thirty experts used a modified Delphi method. The evidence extracted to support the statements was graded according to the GRADE system and reported according to the Revised Standards for Quality Improvement Reporting Excellence guidelines, version 2.0. RESULTS: The POWG reached consensus in six key statements: harmonization of reporting and quality assurance of NGS; molecular tumor board and clinical decision support systems for PO; education and training; research and real-world data collection, patient engagement, regulations, and financial reimbursement of PO treatment strategies; and clinical recommendations and implementation of PO in clinical practice. CONCLUSION: POWG consensus statements standardize the clinical application of NGS CGPs, streamline the interpretation of clinically significant genomic alterations, and align actionable mutations with sequence-directed therapies. The POWG consensus statements may harmonize the utility and delivery of PO in China's GBA.

8 September 2020 in ACS Omega
Verified
Journal Article
Closed access
TKTiffany H. Khaw
Tiffany H. Khaw
SWS. N. Michael Wong
S. N. Michael Wong
GHGenevieve Herle
Genevieve Herle
JDJean Patrick Gonzalez Dahua
Jean Patrick Gonzalez Dahua
ALAdhitya Logan
Adhitya Logan
Anastasia LevitinAnastasia Levitin
Anastasia Levitin